Is this stock a better buy than Woodford Patient Capital Trust plc?

Could this growth investment company outperform Woodford Patient Capital Trust plc (LON:WPCT)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It’s not too easy for the average private investor to gain exposure to the high-growth potential of unquoted early-stage businesses. One option is AIM-listed Mercia Technologies (LSE: MERC), which has a portfolio of investments in 24 such businesses.

The company released its annual results today and I like the look of its business model, the progress it’s making and its current valuation.

Business model

There are two prongs to Mercia’s business model. It’s an asset manager, running third-party investment funds that nurture young businesses. It receives fees for these and other services by which it aims to cover a large chunk of the plc’s operating costs.

As the young businesses develop, it identifies ‘Emerging Stars’ among them and provides direct investment follow­-on capital from its own balance sheet. This is the portfolio of 24 investments I mentioned earlier. It ultimately aims to exit these investments with rich rewards from lucrative flotations or trade sales.


In today’s results, for its financial year ended 31 March, it reported that funds under management increased to £336m from £220m, with revenue rising to £6.7m from £1.8m. Meanwhile, its portfolio of 24 direct investments increased in value to £52m from £38.1m.

The year also saw Mercia demonstrate the viability and potential gains of the direct-investment element of its business model with the trade sale of Allinea Software to ARM, providing an 88.4% uplift on the group’s direct investment cost. The IPO of Concepta (a digital fertility/pregnancy testing business) was another notable event.


When Mercia listed on AIM in December 2014, it raised a net £66m at 50p a share and had a market cap of £106m. Pro forma net assets were just over £75m (34.4p a share), so it was valued at 1.41 times book value.

It raised a further £40m (gross) at 46p a share in February this year and today reported net assets of £121.4m (40.4p a share) at its March year-end. At a current share price of 34p — up 4.6% on the day — the market cap is £102.2m, so it’s now valued at 0.84 times book value.

Despite its increased scale, emerging proof of its business model and management saying today “we can already see several material value inflexion points arising in the coming year,” Mercia is considerably cheaper than at the time it listed on the stock market. It’s also cheaper than a much-higher-profile stock offering exposure to early-stage businesses: Woodford Patient Capital Trust (LSE: WPCT).


At a share price of 97p and with net assets of 100.3p a share, Patient Capital trades at 0.97 times book value. It also happens that Patient Capital has given Mercia the Neil Woodford seal of approval. It owns a 25% stake in Mercia and both companies are chaired by Susan Searle.

With 76 holdings, Patient Capital can be seen as a lower-risk proposition than this article’s other subject, particularly as only about half its holdings are unquoted businesses, with the portfolio also containing some relatively large and familiar quoted names, such as Purplebricks and US-listed Prothena.

Nevertheless, I see Mercia’s 24 investments as reasonable diversification and the company’s third-party fund management arm as providing a useful degree of relative stability. Both businesses have potential to deliver excellent long-term returns for patient investors and I would rate them as ‘buys’ at their current discounts to book value.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Should I buy more Rolls-Royce shares near 500p?

This investor is wondering whether to buy more Rolls-Royce shares this summer or to just stick with those he already…

Read more »

Investing Articles

After its big fall, is the National Grid share price dirt cheap now?

The National Grid share price fell sharply in reponse to new rights issue plans. But is it an even better…

Read more »

Aerial shot showing an aircraft shadow flying over an idyllic beach
Investing Articles

Starting in June, I’d invest £1,000 a month to aim for a £102,000 second income in retirement

This author highlights a less well-known FTSE 100 stock that could help his portfolio generate a very big second income…

Read more »

Investing Articles

Down 47% in 5 years, is the IAG share price due a bounce?

Many companies in the travel sector have seen fierce rallies since 2020. But with the IAG share price still down…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

Despite its drop, I reckon this is one of the best FTSE 100 stocks to buy and hold!

The FTSE 100 has been climbing in 2024 but this favourite of our writer's has been falling. Despite this, she’s…

Read more »

Investing Articles

AI stocks vs EV shares; which is the best sector for me to invest in?

Jon Smith considers the recent rally in AI stocks and weighs up whether to allocate more money there versus EV…

Read more »

A graph made of neon tubes in a room
Investing Articles

Do Greggs shares have even more growth ahead?

Greggs shares have seen some solid growth in the last few months, as the economy shows positive signs. But is…

Read more »

Investing For Beginners

How I’d aim to grow my Stocks & Shares ISA from £20k to £1m

Jon Smith explains how diversification and focusing on sectors for the future can help grow his Stocks and Shares ISA.

Read more »